Literature DB >> 19621616

[Hepatitis E virus seropositivity in hemodialysis patients in Hatay province, Turkey].

Edip Uçar1, Meryem Cetin, Ceren Kuvandik, Mehmet Rami Helvaci, Murat Güllü, Can Hüzmeli.   

Abstract

Hepatitis E virus (HEV) which is mainly transmitted through faecal-oral route, can also be transmitted via parenteral and vertical route. Recent studies suggest zoonotic nature of the virus. The last studies done in Turkey indicate increasing frequency of HEV infection. This study was conducted to determine the rate of anti-HEV seropositivity among patients with terminal stage renal failure undergoing hemodialysis. A total of 92 patients (54 male, 38 female; age range: 22-71 years, mean age: 55 +/- 11 years) who had undergone hemodialysis for a mean period of 66 +/- 18 months, were included to the study. HEV antibodies were analyzed using anti-HEV IgG enzyme immunoassay (ELISA, Dia.Pro Diagnostic Bioprobes, Italy). In order to study the relationship of anti-HEV positivity between hepatitis C virus and hepatitis B virus infections, anti-HCV antibody and HBsAg were also considered. Mean age, duration of hemodialysis, platelet, serum albumin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, blood transfusion history were the other evaluated parameters. Anti-HEV IgG positivity was detected in 19 (20.6%) patients, while 7 (7.6%) had anti-HCV positivity and 4 (4.3%) had HBsAg positivity. No statistically significant relation was determined between anti-HEV IgG positive and negative patients in terms of hemodialysis duration, blood transfusion, other laboratory findings and anti-HCV and HBsAg positivity (p > 0.05). While the anti-HEV seropositivity rate (20.6%) determined in this study was higher than the rates determined in the same group of patients in the western part of the country (10-16%), the rate was similar to the rates reported from the southeastern part (23%) of Turkey. It can be concluded that screening of patients before or during hemodialysis in terms of anti-HEV antibodies, seems to be of crucial importance in order to establish necessary precautions to prevent parenteral and/or nosocomial transmission of HEV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19621616

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  9 in total

Review 1.  Hepatitis E virus in the countries of the Middle East and North Africa region: an awareness of an infectious threat to blood safety.

Authors:  Soha Yazbek; Khalil Kreidieh; Sami Ramia
Journal:  Infection       Date:  2015-06-26       Impact factor: 3.553

Review 2.  Epidemiology of hepatitis E virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

3.  The Prevalence of Hepatitis E Virus Infection in the Adult Turkish Population: A Systematic Review of the Literature and Prevalence Study in Blood Donors in Mersin Province.

Authors:  Orhan Sezgin; Serkan Yaraş; Seda Tezcan Ülger; Gönül Aslan; Eyyüp Naci Tiftik
Journal:  Turk J Gastroenterol       Date:  2021-09       Impact factor: 1.555

Review 4.  Epidemiology of Hepatitis E Virus in European Countries.

Authors:  Daniele Lapa; Maria Rosaria Capobianchi; Anna Rosa Garbuglia
Journal:  Int J Mol Sci       Date:  2015-10-27       Impact factor: 5.923

5.  Prevalence of anti-hepatitis E virus IgG antibodies in sera from hemodialysis patients in Tripoli, Lebanon.

Authors:  Mohamad Bachar Ismail; Imad Al Kassaa; Dima El Safadi; Sarah Al Omari; Hassan Mallat; Fouad Dabboussi; Monzer Hamze
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

Review 6.  Seroprevalence of Hepatitis E Virus Infection in Middle Eastern Countries: A Systematic Review and Meta-Analysis.

Authors:  Fadi S Qashqari
Journal:  Medicina (Kaunas)       Date:  2022-07-06       Impact factor: 2.948

7.  Anti-Hepatitis E Antibody in Hemodialysis Patients in Isfahan, Iran: Prevalence and Risk Factors.

Authors:  Seyed Moayed Alavian; Behrooz Ataei; Ali Ebrahimi; Omid Pirhaji; Roya Azad; Behrooz Olya; Amir Mohammad Ataei
Journal:  Hepat Mon       Date:  2015-09-08       Impact factor: 0.660

Review 8.  Transmission of Hepatitis E Virus in Developing Countries.

Authors:  Mohammad S Khuroo; Mehnaaz S Khuroo; Naira S Khuroo
Journal:  Viruses       Date:  2016-09-20       Impact factor: 5.048

Review 9.  Hepatitis E virus infection in Turkey: a systematic review.

Authors:  Hakan Leblebicioglu; Resat Ozaras
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-05-02       Impact factor: 3.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.